Andain Inc. Announces its Innovative Organ-targeted Drug Delivery Nano-particles

Apr 29, 2013, 09:30 ET from Andain Inc

ARAD, Israel, April 29, 2013 /PRNewswire/ --

Andain Inc. (OTCBB: ANDN) ("Andain" or the "Company"), a company engaged in commercializing novel technologies in biotech, medical and life sciences fields through its accelerating incubator program, announces today its innovative nano-particles drug delivery technology.

Andain completed the development of innovative lipid-based drug delivery nano-particles capable of carrying hydrophilic and hydrophobic drugs to a targeted human organ with timely drug release capabilities. After the nano-particles release the drug directly to the targeted organ, they brake-down to their natural ingredients and are absorbed into the natural metabolism with no adverse affects.  

The Company has  successfully developed an inhaled solution for the treatment of COPD (Chronic Obstructive Pulmonary Disease), which affects over 16 million patients in the USA alone, and is the No. 4 clinical cause of death after heart failure, cancer and stroke.

The Company intends to approach the initial market segment of respiratory intensive care units to treat VAP (ventilator-associated pneumonia),  which is commonly associated with  multi-drug-resistant (MDR) virulent bacteria causing over than 50% mortality rate.

"Our initial human respiratory tests show superb lung dispersion and distribution, preventing any residual damage providing safe and extremely efficient respiratory drug delivery method   capable to carry any combinations of drugs" said Andain President and CEO Sam Elimelech. "We have a developed efficient delivery system capable to deliver almost any drug usually systemically administered to be targeted to a specific organ and enabling to dramatically reduce the needed treatment dosage".  

Established in 2004 as a Nevada corporation with locations in Israel and the US, Andain commercializes novel technologies in the biotechnology and medical fields, specializing in identifying technical innovations and providing a unique incubator/accelerator development and industrial platform. The Company also offers technical know-how and business strategy expertise to commercialize new technologies and deliver shareholder value

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Form 10-K filing and other filings with the U S. Securities and Exchange Commission (available at The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

Sam Elimelech, President & CEO
Andain Inc

SOURCE Andain Inc